Prior Authorization May Reduce Access to Important Heart Failure Drugs

Why It Matters

Prior‑authorization delays reduce timely use of life‑saving heart‑failure therapies, widening outcome gaps for vulnerable populations and prompting insurers to reconsider cost‑control tactics.

Key Takeaways

• Prior auth needed for 12% ARNI, 14% SGLT2i prescriptions.
• Black and Hispanic patients face higher prior‑auth rates.
• Authorization delays triple ARNI fill time, septuple SGLT2i.
• SGLT2i never filled twice as often with prior auth.
• Findings suggest policy may worsen heart‑failure disparities.

Pulse Analysis

Heart‑failure treatment guidelines now prioritize angiotensin receptor‑neprilysin inhibitors (ARNIs) and sodium‑glucose cotransporter‑2 inhibitors (SGLT2is) for their proven mortality benefits. Insurers often employ prior‑authorization protocols to steer patients toward cheaper alternatives, but these controls can unintentionally obstruct access to the most effective therapies. Understanding the balance between cost containment and clinical efficacy is essential for providers navigating formularies and for payers aiming to maintain value‑based care.

The recent analysis of over 2,100 patients across large health systems reveals stark inequities: prior‑authorization requests were more frequent among Black and Hispanic individuals and those lacking Medicare coverage. Delays of three to seven times longer for prescription fulfillment translated into a two‑fold increase in patients never receiving SGLT2i therapy. Such gaps not only jeopardize individual outcomes but also amplify systemic disparities, potentially increasing hospitalizations and overall healthcare expenditures.

These findings signal a need for policy reform. Payers could adopt streamlined authorization pathways, automatic approvals for guideline‑endorsed drugs, or value‑based contracts that align cost with outcomes. Meanwhile, clinicians should advocate for patients by documenting medical necessity early and exploring patient assistance programs. Ongoing research into copays and coinsurance will further illuminate financial barriers, guiding a more equitable approach to heart‑failure management that preserves both clinical benefit and fiscal responsibility.